Table 1.
Characteristics of the overall cohort.
| Characteristics | N Total (%) | LUMC | GUH | p-Value |
|---|---|---|---|---|
| Total | 82 | 53 (65) | 29 (35) | |
| Sex | 0.20 | |||
| Male | 50 (61) | 35 (66) | 15 (52) | |
| Female | 32 (39) | 18 (34) | 14 (48) | |
| Age group | 0.16 | |||
| Children (0–<16 yrs) | 35 (43) | 19 (36) | 16 (55) | |
| AYA (16–<40 yrs) | 35 (43) | 24 (45) | 11 (38) | |
| Older adults (≥40 yrs) | 12 (15) | 10 (19) | 2 (7) | |
| Location tumor | 86 | 0.10 | ||
| Lower extremity | 68 (83) | 41 (77) | 27 (93) | |
| Upper extremity | 7 (9) | 5 (9) | 2 (7) | |
| Axial skeleton | 7 (9) | 7 (13) | 0 | |
| Tumor size | 0.92 | |||
| Small (≤8 cm) | 39 (48) | 25 (47) | 14 (48) | |
| Large (>8 cm) | 43 (52) | 28 (53) | 15 (52) | |
| Metastases at presentation | 0.98 | |||
| No | 70 (85) | 46 (87) | 24 (83) | |
| Yes | 12 (12) | 7 (13) | 5 (17) | |
| Preoperative CTx treatment | 81 | 52 | 29 | 0.17 |
| 1 MAP or 2 AP completed | 4 (5) | 4 (8) | 0 (0) | |
| 2 MAP or 3 AP completed | 71 (87) | 43 (83) | 28 (97) | |
| >2 MAP or >3 AP completed | 6 (7) | 5 (10) | 1 (3) | |
| Histological response to CTx | 0.20 | |||
| Poor (≥10% viable tumor cells) | 43 (52) | 25 (47) | 18 (62) | |
| Good (<10% viable tumor cells) | 39 (39) | 28 (53) | 11 (38) | |
| Radiological response to CTx | 0.49 | |||
| Poor response (rWIR < 2.3) | 41 (50) | 28 (53) | 13 (45) | |
| Good response (rWIR ≥ 2.3) | 41 (50) | 25 (47) | 16 (55) | |
| Local recurrence | 0.38 | |||
| No | 73 (89) | 46 (78) | 27 (93) | |
| Yes | 9 (11) | 7 (13) | 2 (7) | |
| Metastases during follow-up | 0.06 | |||
| No | 51 (62) | 29 (55) | 22 (76) | |
| Yes | 31 (38) | 24 (45) | 7 (24) |
AYA = adolescents and young adults; yrs = years; MAP = Methotrexate, Adriamycin, and Cisplatin; AP = Adriamycin and Cisplatin; CTx = chemotherapy; and rWIR = relative wash-in rate.